As of May 25
| +1.01 / +3.87%|
The 16 analysts offering 12-month price forecasts for Valeant Pharmaceuticals have a median target of 44.50, with a high estimate of 102.00 and a low estimate of 18.00. The median estimate represents a +64.09% increase from the last price of 27.12.
The current consensus among 20 polled investment analysts is to Hold stock in Valeant Pharmaceuticals. This rating has held steady since May, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.